Sapropterin as a Treatment for Autistic Disorder

• ClinicalTrials.gov Identifier: NCT00850070
• Recruitment Status: Completed
• First Posted: February 24, 2009
• Results First Posted: February 28, 2014
• Last Update Posted: May 1, 2018
• Sponsor: The Children's Health Council
• Collaborator: BioMarin Pharmaceutical
• Information provided by (Responsible Party): Glen R. Elliott, The Children's Health Council

Study Description

Brief Summary:

This study is intended to provide a definitive test of the hypothesis that elevating sapropterin (tetrahydrobiopterin, a cofactor for several key brain enzymes)concentrations in the CNS will result in measurable improvements in core symptoms of autism in young individuals, under age 6 years. The study will entail a double-blind, placebo-controlled 16-week intervention.

Condition or disease	Intervention/treatment	Phase
Autistic Disorder	Drug: sapropterin; Drug: Placebo	Phase 2

Detailed Description:

Over the past 20 years, several studies have suggested that sapropterin (tetrahydrobiopterin) might ameliorate core symptoms of autism at least in young (under age 6) subjects. However, those studies had somewhat questionable methodologies, a major one being that the doses of sapropterin used were roughly one tenth that thought to be needed to provide physiologically meaningful increases of sapropterin in the central nervous system (CNS). This study will look at the impact of a sustained exposure to this higher dose in well-diagnosed young children with autism.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 46 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Sapropterin as a Treatment for Autistic Disorder: A Phase II Randomized, Double-Blind, Placebo-Controlled Trial
• Study Start Date: March 2009
• Actual Primary Completion Date: August 2011
• Actual Study Completion Date: October 2011

Arms and Interventions

Arm	Intervention/treatment
Experimental: sapropterin, 100 mg capsules; Sapropterin was supplied as a 100 mg tablet and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.	Drug: sapropterin; Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks; Other Names: Kuvan; tetrahydrobiopterin
Placebo Comparator: Placebo, matching active drug; The placebo was supplied as a 100 mg tablet, and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.	Drug: Placebo; Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.; Other Name: sugar pill

Outcome Measures

Primary Outcome Measures :

1. Clinical Global Impression -- Improvement (CGI-I) Scale [ Time Frame: Weekly for 4 weeks, then monthly, with 16-week end point. Primary outcome assessment used two time points, baseline and 16 weeks. ]
   The CGI-I assessed the number of participants showing much or very much improvement on the CGI-I scale. This is a summary judgment made by a trained clinician based on observed and reported behaviors of the child compared to baseline. It is a 7-point scale from very much worse (1) to very much improved (7). Chi-square analyses were used to assess change in CHI-I scores (by group, post-test). Mixed-effects regression models via SPSS MIXED determined the main effects attributed to differences by group (BH4 and placebo), time (treated as categorical at levels baseline, 8 weeks, and 16 weeks) and the group-by-time interaction. We used random intercept and trend modeling that accounts for each individual's initial level of symptom severity/functioning and rate of change/time
2. Clinical Global Impression -- Severity (CGI-S) Scale [ Time Frame: Baseline, 8 weeks, and 16 weeks. Primary outcome assessment used 2 time points, baseline and 16 weeks. ]
   The CGI-S assessed the number of participants with improved severity illness on the CGI-S scale. This is a summary judgment made by a trained clinician of symptom severity. It is a 7-point scale that rates the severity of the patient's illness at time of assessment with 1 - normal, not at all, to 7 - extremely ill. Mixed-effects regression models via SPSS MIXED determined the main effects attributed to differences by group (BH4 and placebo), time (treated as categorical at levels baseline, 8 weeks, and 16 weeks) and the group-by-time interaction. We used random intercept and trend modeling that accounts for each individual's initial level of symptom severity/functioning and rate of change/time

Secondary Outcome Measures :

1. Preschool Language Scale-Fourth Edition (PLS-4). Assesses Expressive and Receptive Language Skills in Ages Birth Through 6 Years, 11 Months. [ Time Frame: Primary outcome assessment examined the difference in scores between baseline and week 16. ]
   Measures expressive & receptive language and total scores in ages birth to 6 years 11 months. The scales generate raw, standard, and age-equivalent scores; raw scores for the total scale were selected for use in this study. Total is average of subscales. Minimum raw score = 0, maximum = 130. Higher scores indicate better language abilities. Mixed-effects regression models via SPSS MIXED determined the main effects attributed to differences by group (BH4 and placebo), time (treated as categorical at levels baseline, 8 weeks, and 16 weeks) and the group-by-time interaction. For the outcome effect, the difference between baseline and 16 weeks was determined as an indicator for change.
2. Vineland Adaptive Behavior Scale-II. [ Time Frame: Primary outcome assessment used two time points, baseline and 16 weeks. ]
   the Vineland-2 is a semi-structured interview designed to assess communicatino, daily living, socialization and motor skills. The Vineland-2 is comprised of a total Adaptive Composite scale; we chose to use 10 subscales that specifically address functional domains relevant for a young ASD sample - Receptive Communication, Expressive Communication, Personal Daily Living Skills, Domestic Daily Living Skills, Community Daily Living Skills, Interpersonal Relations, Play Skills, Coping Skills, Gross Motor Skills, Fine Motor Skills. Scales generate raw or sum, V-, and age-equivalent scores; raw scores were selected for use in the study. Raw score ranges from 0 to 108 depending on the scale. Total raw scale range is from 0 to 766. Subscale scores are averaged to create the total adaptive behavior composite. Higher subscale scores indicate more skills. Difference between baseline and week 16 was used as an indicator of change.
3. Children's Yale Brown Obsessive Compulsive Scale (C-YBOCS) [ Time Frame: Baseline, 8 weeks, and 16 weeks ]
   The C-YBOCS is a scale is designed to rate the severity of obsessive and compulsive symptoms in children and adolescents, ages 6 to 17 years. It can be administered by a clinican or trained interviewer in a semi-structured fashion. In general, the ratings depend on the child's and parent's report; however, the final rating is based on the clinical judgement of the interviewer. Rate the characteristics of each item over the prior week up until, and including, the time of the interview. Scores should reflect the average of each item for the entire week, unless otherwise specified.
4. Connor's Preschool ADHD Questionnaire [ Time Frame: Baseline, 8 weeks, and 16 weeks ]
   Conners Early Childhood, addresses child behavior for ages 2 years to 6 years with a variety of scales, including an ADHD subdomain.
5. Adverse Events Scale [ Time Frame: Every 1-2 weeks for 16 weeks ]
   This was not a standardized scale but a set of questions that was asked of each family - some standard and others open ended.
6. Aberrant Behavior Checklist (ABC) - Inappropriate Speech [ Time Frame: Primary outcome assessment used two time points, baseline and 16 weeks. ]
   Subscale assessing echolalia & other odd speech. Higher subscale scores indicate more symptoms. 4 items comprise the subscale, with range of scores from 0-4. Total score range on this subscale is 0 to 16. Scores are averaged to compute overall score. Difference in scores between baseline and week 16 were used as indicator of change.
7. Social Responsiveness Scale (SRS) [ Time Frame: Primary outcome assessment used two time points, baseline and 16 weeks. ]
   The SRS is a 65-item scale used to measure the severity of symptoms in ASD as they occur in natural social settings. The SRS is comprised of 1 Total scale and 5 subscales that generate raw scores that can be converted to standard T-scores (with mean of 50 and standard deviation of 10) for gender and rater type; standard scores were selected for use in this study. A total T-score of 76 or higher is considered severe and strongly associated with a clinical diagnosis of autistic disorder. A t-score of 60-75 is in the mild to moderate range and considered typical for children with mild or 'high-functioning' ASD, while a T-score of 59 or less suggests an absence of ASD symptoms. A total raw score of >75 were associated with a sensitivity value of .85 and a specificity value of .75 for ASD. Difference in scores between baseline and week 16 were used as an indicator of change.
8. Parent Global Assessment (PGA) Scale [ Time Frame: Baseline, 8 weeks, and 16 weeks ]
   This is a measure where parents rate their impression of their child's improvement, in a global manner.

Eligibility Criteria

• Ages Eligible for Study: 3 Years to 6 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Parents sign informed consent
• Child meets criteria for autistic disorder (based on score on the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS), given by a certified administrator, research reliable)
• Child has a Developmental Quotient (DQ) ≥ 50 (Vineland Adaptive Scales, Interview Edition)
• Parents agree to delay initiation of other treatments during double-blind trial

Exclusion Criteria:

• Child has had seizures in past 6 months or a change in seizure medications in past 4 weeks.
• Child has > 18 points on subscale of (Autism Behavior Checklist) ABC-I
• Child is taking any psychoactive medication other than supplements, anticonvulsants, or soporifics (melatonin, diphenhydramine)
• Child has had any change in standing medications in the past 4 weeks.
• Child has known genetic disorders
• Child has known severe neurological disorders, including cerebral palsy

Contacts and Locations

Locations

United States, California

The Children's Health Council

Palo Alto, California, United States, 94304

Sponsors and Collaborators

The Children's Health Council

BioMarin Pharmaceutical

Investigators

• Principal Investigator: Glen R Elliott, Ph.D., M.D.; The Children's Health Council

More Information

Publications of Results:

Klaiman C, Huffman L, Masaki L, Elliott GR. Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2013 Jun;23(5):320-8. doi: 10.1089/cap.2012.0127.

• Responsible Party: Glen R. Elliott, Chief Psychiatrist and Medical Director, The Children's Health Council
• ClinicalTrials.gov Identifier: NCT00850070
• Other Study ID Numbers: CHC-0901
• First Posted: February 24, 2009
• Results First Posted: February 28, 2014
• Last Update Posted: May 1, 2018
• Last Verified: April 2018

Keywords provided by Glen R. Elliott, The Children's Health Council:

autism

Additional relevant MeSH terms:

Autistic Disorder; Autism Spectrum Disorder; Child Development Disorders, Pervasive; Neurodevelopmental Disorders; Mental Disorders